Back to Search Start Over

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Authors :
Lee, Rebecca J
Wysocki, Oskar
Zhou, Cong
Shotton, Rohan
Tivey, Ann
Lever, Louise
Woodcock, Joshua
Albiges, Laurence
Angelakas, Angelos
Arnold, Dirk
Aung, Theingi
Banfill, Kathryn
Baxter, Mark
Barlesi, Fabrice
Bayle, Arnaud
Besse, Benjamin
Bhogal, Talvinder
Boyce, Hayley
Britton, Fiona
Calles, Antonio
Castelo-Branco, Luis
Copson, Ellen
Croitoru, Adina E
Dani, Sourbha S
Dickens, Elena
Eastlake, Leonie
Fitzpatrick, Paul
Foulon, Stephanie
Frederiksen, Henrik
Frost, Hannah
Ganatra, Sarju
Gennatas, Spyridon
Glenthøj, Andreas
Gomes, Fabio
Graham, Donna M
Hague, Christina
Harrington, Kevin
Harrison, Michelle
Horsley, Laura
Hoskins, Richard
Huddar, Prerana
Hudson, Zoe
Jakobsen, Lasse H.
Joharatnam-Hogan, Nalinie
Khan, Sam
Khan, Umair T
Khan, Khurum
Massard, Christophe
Maynard, Alec
McKenzie, Hayley
Michielin, Olivier
Mosenthal, Anne C
Obispo, Berta
Patel, Rushin
Pentheroudakis, George
Peters, Solange
Rieger-Christ, Kimberly
Robinson, Timothy
Rogado, Jacobo
Romano, Emanuela
Rowe, Michael
Sekacheva, Marina
Sheehan, Roseleen
Stevenson, Julie
Stockdale, Alexander
Thomas, Anne
Turtle, Lance
Viñal, David
Weaver, Jamie
Williams, Sophie
Wilson, Caroline
Palmieri, Carlo
Landers, Donal
Cooksley, Timothy
Dive, Caroline
Freitas, André
Armstrong, Anne C
Institut Gustave Roussy (IGR)
Oncologie gynécologique
Département de médecine oncologique [Gustave Roussy]
Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR)
Physikalisch-Technische Bundesanstalt [Braunschweig] (PTB)
Centre de Recherche en Cancérologie de Marseille (CRCM)
Aix Marseille Université (AMU)-Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Cancer Research and Personalized Medicine - CARPEM [Paris]
Hôpital Européen Georges Pompidou [APHP] (HEGP)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Necker - Enfants Malades [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Genetics
University of Southampton
Centre de recherche en épidémiologie et santé des populations (CESP)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Hematology
Odense University Hospital
Department of Clinical Microbiology [Rigshospitalet]
Rigshospitalet [Copenhagen]
Copenhagen University Hospital-Copenhagen University Hospital
University of Manchester [Manchester]
Lausanne University Hospital
Department of Medical Oncology
Ioannina University Hospital
Immunité et cancer (U932)
Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
University of Liverpool
Clinical and Experimental Pharmacology Group
Paterson Institute for Cancer Research, University of Manchester
Universidade Estadual de Campinas = University of Campinas (UNICAMP)
Cancer Research UK Department of Medical Oncology
Christie Hospital NHS Foundation Trust
Source :
Lee, R J, Wysocki, O, Zhou, C, Shotton, R, Tivey, A, Lever, L, Woodcock, J, Albiges, L, Angelakas, A, Arnold, D, Aung, T, Banfill, K, Baxter, M, Barlesi, F, Bayle, A, Besse, B, Bhogal, T, Boyce, H, Britton, F, Calles, A, Castelo-Branco, L, Copson, E, Croitoru, A E, Dani, S S, Dickens, E, Eastlake, L, Fitzpatrick, P, Foulon, S, Frederiksen, H, Frost, H, Ganatra, S, Gennatas, S, Glenthøj, A, Gomes, F, Graham, D M, Hague, C, Harrington, K, Harrison, M, Horsley, L, Hoskins, R, Huddar, P, Hudson, Z, Jakobsen, L H, Joharatnam-Hogan, N, Khan, S, Khan, U T, Khan, K, Massard, C, Maynard, A, McKenzie, H, Michielin, O, Mosenthal, A C, Obispo, B, Patel, R, Pentheroudakis, G, Peters, S, Rieger-Christ, K, Robinson, T, Rogado, J, Romano, E, Rowe, M, Sekacheva, M, Sheehan, R, Stevenson, J, Stockdale, A, Thomas, A, Turtle, L, Viñal, D, Weaver, J, Williams, S, Wilson, C, Palmieri, C, Landers, D, Cooksley, T, ESMO Co-Care, Dive, C, Freitas, A & Armstrong, A C 2022, ' Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital ', JCO Clinical Cancer Informatics, vol. 6, e2100177 . https://doi.org/10.1200/CCI.21.00177, Lee, R J, Robinson, T, Wysocki, O, Zhou, C, Shotton, R & Tivey, A 2022, ' Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital ', American Society of Clinical Oncology, vol. 6, e2100177, pp. 1-18 . https://doi.org/10.1200/CCI.21.00177, JCO Clinical Cancer Informatics, JCO Clinical Cancer Informatics, 2022, 6, ⟨10.1200/CCI.21.00177⟩
Publication Year :
2022

Abstract

PURPOSE Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early intervention are critical. We sought to identify features of COVID-19 disease in patients with cancer predicting severe disease and build a decision support online tool, COVID-19 Risk in Oncology Evaluation Tool (CORONET). METHODS Patients with active cancer (stage I-IV) and laboratory-confirmed COVID-19 disease presenting to hospitals worldwide were included. Discharge (within 24 hours), admission (≥ 24 hours inpatient), oxygen (O2) requirement, and death were combined in a 0-3 point severity scale. Association of features with outcomes were investigated using Lasso regression and Random Forest combined with Shapley Additive Explanations. The CORONET model was then examined in the entire cohort to build an online CORONET decision support tool. Admission and severe disease thresholds were established through pragmatically defined cost functions. Finally, the CORONET model was validated on an external cohort. RESULTS The model development data set comprised 920 patients, with median age 70 (range 5-99) years, 56% males, 44% females, and 81% solid versus 19% hematologic cancers. In derivation, Random Forest demonstrated superior performance over Lasso with lower mean squared error (0.801 v 0.807) and was selected for development. During validation (n = 282 patients), the performance of CORONET varied depending on the country cohort. CORONET cutoffs for admission and mortality of 1.0 and 2.3 were established. The CORONET decision support tool recommended admission for 95% of patients eventually requiring oxygen and 97% of those who died (94% and 98% in validation, respectively). The specificity for mortality prediction was 92% and 83% in derivation and validation, respectively. Shapley Additive Explanations revealed that National Early Warning Score 2, C-reactive protein, and albumin were the most important features contributing to COVID-19 severity prediction in patients with cancer at time of hospital presentation. CONCLUSION CORONET, a decision support tool validated in health care systems worldwide, can aid admission decisions and predict COVID-19 severity in patients with cancer.

Details

Language :
English
ISSN :
24734276
Database :
OpenAIRE
Journal :
Lee, R J, Wysocki, O, Zhou, C, Shotton, R, Tivey, A, Lever, L, Woodcock, J, Albiges, L, Angelakas, A, Arnold, D, Aung, T, Banfill, K, Baxter, M, Barlesi, F, Bayle, A, Besse, B, Bhogal, T, Boyce, H, Britton, F, Calles, A, Castelo-Branco, L, Copson, E, Croitoru, A E, Dani, S S, Dickens, E, Eastlake, L, Fitzpatrick, P, Foulon, S, Frederiksen, H, Frost, H, Ganatra, S, Gennatas, S, Glenthøj, A, Gomes, F, Graham, D M, Hague, C, Harrington, K, Harrison, M, Horsley, L, Hoskins, R, Huddar, P, Hudson, Z, Jakobsen, L H, Joharatnam-Hogan, N, Khan, S, Khan, U T, Khan, K, Massard, C, Maynard, A, McKenzie, H, Michielin, O, Mosenthal, A C, Obispo, B, Patel, R, Pentheroudakis, G, Peters, S, Rieger-Christ, K, Robinson, T, Rogado, J, Romano, E, Rowe, M, Sekacheva, M, Sheehan, R, Stevenson, J, Stockdale, A, Thomas, A, Turtle, L, Viñal, D, Weaver, J, Williams, S, Wilson, C, Palmieri, C, Landers, D, Cooksley, T, ESMO Co-Care, Dive, C, Freitas, A & Armstrong, A C 2022, ' Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital ', JCO Clinical Cancer Informatics, vol. 6, e2100177 . https://doi.org/10.1200/CCI.21.00177, Lee, R J, Robinson, T, Wysocki, O, Zhou, C, Shotton, R & Tivey, A 2022, ' Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital ', American Society of Clinical Oncology, vol. 6, e2100177, pp. 1-18 . https://doi.org/10.1200/CCI.21.00177, JCO Clinical Cancer Informatics, JCO Clinical Cancer Informatics, 2022, 6, ⟨10.1200/CCI.21.00177⟩
Accession number :
edsair.doi.dedup.....96ad3479ad229bf2a84cd91384660fd9